Novo Nordisk shares drop sharply after the company reports that ziltivekimab, an experimental heart medicine, fails to deliver statistically meaningful results in a late-stage clinical trial. According to Novo Nordisk, ziltivekimab does not significantly reduce major cardiovascular adverse events compared with placebo. CNBC reports the stock falls about 9% following the announcement, reflecting investor reaction to the lack of benefit. Quartz similarly reports that the drug does not reduce major adverse cardiovascular events versus placebo in the study. Both outlets cite the trial’s large patient population—more than 6,300 participants—and describe the outcome as a failure to meet the study’s primary effectiveness goal. The company’s disclosure indicates that the medication’s anti-inflammatory approach does not translate into the expected reduction in major cardiovascular outcomes. The results shape the next steps for the program, but the articles focus on the trial outcome and the immediate market response rather than changes to timelines or regulatory plans.